Particle.news
Health ❯ Healthcare ❯ Cancer Research
Checkpoint Inhibitors Cancer Treatment Mathematical Modeling Immune Checkpoint Inhibitors Pembrolizumab Therapeutic Targets Glypican-3 Targeting PD-1 Blockade Antibody-Drug Conjugates T Cell Therapy Monoclonal Antibodies Tumor Immune Evasion PD-1 Inhibitors
The decision follows phase 3 data showing the regimen extends progression-free and overall survival compared with atezolizumab alone.
